Shr-8068
Immunotherapy
Shanghai Zhongshan HospitalPhase 2Active
CCC
51/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 73/ 100
Competitive context
69 Active assets in the Immunotherapy cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Serplulimab Tao Zhang | Phase 3 | BB |
Pembrolizumab Ismail Gögenur | Phase 4 | BB |
LENVATINIB The First Affiliated Hospital with Nanjing Medical University | Phase 4 | BB |
Rivoceranib Fudan University | Phase 3 | B |
Nivolumab Fondazione Policlinico Universitario Agostino Gemelli IRCCS | Phase 4 | B |
View all 50 →
Same molecule, other indications
Shr-8068 is also rated in:
Resectable Hepatocellular Carcinoma With Intermediate or High Recurrence RiskDormant
CCC
Indicative ·
53 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →